Biotechnology company Halozyme Therapeutics Inc (NASDAQ:HALO) stated on Tuesday that its net income was USD63m (USD0.45 per share) for the full-year ended 31 December 2017.
This reflects an improvement when compared with a net loss of USD103m (USD0.81 per share) in 2016.
Revenue of USD316.6m was generated for the full-year ended 31 December 2017, up over revenue of USD146.7m in 2016.
Research and development expenses of USD150.6m were recorded for the full-year ended 31 December 2017, almost flat from R&D of USD150.8m in 2016.
TiumBio files Clinical Trial Application to start Phase 1b TU7710 study
Moderna reports positive interim results from next-generation COVID-19 vaccine trial
Scancell initiates SCOPE trial's iSCIB1+ cohort
Valneva launches Phase 1 trial for next-generation Zika vaccine
argenx obtains VYVGART approval for primary immune thrombocytopenia in Japan
Bio-Thera Solutions' BAT8006 phase II Study receives US FDA IND approval